| Literature DB >> 35743780 |
Francesco Ferrara1, Valentina Capone2,3, Filippo Cademartiri4, Olga Vriz5, Rosangela Cocchia2, Brigida Ranieri6, Monica Franzese6, Rossana Castaldo6, Antonello D'Andrea7, Rodolfo Citro8, Salvatore Chianese2, Roberto Annunziata2, Flavio Marullo2, Mario Siniscalchi2, Marianna Conte2, Chiara Sepe2, Renato Maramaldi2, Salvatore Rega9, Giuseppe Russo10, Massimo Majolo10, Eliana Raiola10, Andrea Salzano6, Ciro Mauro2, Bruno Trimarco3, Raffaele Izzo3, Eduardo Bossone2.
Abstract
BACKGROUND: Myocardial mechano-energetic efficiency (MEE) is the capability of the left ventricle (LV) to convert the chemical energy obtained from the cardiac oxidative metabolism into mechanical work. The aim of present study was to establish normal non-invasive MEE and MEEi reference values.Entities:
Keywords: echocardiography; indexed myocardial mechanical efficiency; myocardial mechanical efficiency
Year: 2022 PMID: 35743780 PMCID: PMC9224845 DOI: 10.3390/jpm12060996
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
Demographic and clinical characteristics of the study population.
| Variable | Overall Population | Range | Women | Men | |
|---|---|---|---|---|---|
| Age (years) | 45.4 ± 15.6 (46) | 16–92 | 46.2 ± 15.4 | 44.6 ± 15.8 | 0.075 |
| Height (cm) | 168.6 ± 9.5 (168) | 144–198 | 162.4 ± 6.7 | 175.5 ± 7.1 | 0.0001 |
| Weight (Kg) | 69.7 ± 12.0 (70) | 41–113 | 62.7 ± 8.8 | 77.3 ± 10.4 | 0.0001 |
| BMI (kg/m2) | 24.4 ± 3.1 (24.2) | 24.2–32.8 | 23.8 ± 3.24 | 25.1 ± 2.8 | 0.0001 |
| BSA (m2) | 1.79 ± 0.19 (1.78) | 1.06–2.76 | 1.67 ± 0.14 | 1.92 ± 0.16 | 0.0001 |
| SBP (mmHg) | 123.9 ± 12.1 (125) | 84–145 | 121.8 ± 12.7 | 126.1 ± 10.9 | 0.0001 |
| DBP (mmHg) | 76.1 ± 8.5 (78.5) | 44–91 | 75.0 ± 8.4 | 77.2 ± 8.3 | 0.0001 |
| MBP (mmHg) | 92.0 ± 8.7 (93.3) | 57.3–110.6 | 90.6 ± 8.9 | 93.5 ± 8.1 | 0.0001 |
| PP (mmHg) | 47.7 ± 9.7 (48) | 20–80 | 46.8 ± 9.6 | 48.8 ± 9.7 | 0.001 |
| HR (b/m) | 71.1 ± 11.6 (70) | 45–105 | 73.3 ± 10.8 | 68.7 ± 11.9 | 0.025 |
HR, heart rate; BMI, body mass index; BP, blood pressure; BSA, body surface area; DBP, diastolic blood pressure; MBP, mean blood pressure; PP, pulse pressure; SBP, systolic blood pressure; p values indicate sex-related differences.
Echocardiographic parameters of the study population.
| Parameters | Overall Population (Mean ± SD) | Women | Men | |
|---|---|---|---|---|
| Septal wall thickness in diastole (mm) | 8.6 ± 1.4 (6–11) | 8.3 ± 1.3 | 9.0 ± 1.3 | 0.0001 |
| Inferolateral wall thickness in diastole (mm) | 8.6 ± 1.3 (6–11) | 8.3 ± 1.2 | 9.0 ± 1.3 | 0.0001 |
| LV end-diastolic diameter (mm) | 47.3 ± 5.0 (36–58) | 45.0 ± 4.2 | 49.8 ± 4.5 | 0.0001 |
| LV EDV (mL) | 80.5 ± 25.8 (41–158) | 67.7 ± 18.0 | 94.6 ± 25.8 | 0.0001 |
| LV ESV (mL) | 29.4 ± 11.0 (11–72) | 24.6 ± 7.9 | 34.7 ± 11.6 | 0.0001 |
| LV EF (biplane) (%) | 63.9 ± 5.6 (50–79) | 64.1 ± 5.3 | 63.7 ± 6.0 | 0.226 |
| LV mass index (g/m2) | 77.0 ± 16.5 (38–145) | 72.1 ± 14.9 | 82.7 ± 16.5 | 0.0001 |
| LAVI (mL/m2) | 20.4 ± 5.6 (8.5–46.0) | 20.0 ± 5.2 | 20.8 ± 6.1 | 0.024 |
| Mitral Peak E/e’ ratio | 5.9 ± 1.7 (2.2–11.8) | 6.1 ± 1.8 | 5.7 ± 1.7 | 0.0001 |
| SVI (mL/m2) | 38.7 ± 7.4 (22.0–73.1) | 39.1 ± 6.7 | 38.3 ± 7.9 | 0.121 |
| CI (L/min/m2) | 2.7 ± 0.6 (1.73 −5.7) | 2.8 ± 0.6 | 2.5 ± 0.6 | 0.0001 |
| RV basal diameter (mm) | 33.2 ± 3.6 | 32.0 ± 3.3 | 34.7 ± 3.3 | 0.0001 |
| RV mid cavity diameter (mm) | 25.8 ± 3.8 | 24.6 ± 3.2 | 27.3 ±3.9 | 0.0001 |
| RV longitudinal diameter (mm) | 63.8 ± 5.0 | 62.1 ± 4.1 | 65.4 ± 5.3 | 0.0001 |
| RA major dimension (mm) | 41.3 ± 4.6 | 39.9 ± 4.2 | 42.8 ± 4.6 | 0.0001 |
| RA minor dimension (mm) | 33.4 ± 4.4 | 31.9 ± 3.5 | 35.1 ± 4.6 | 0.0001 |
| Tricuspid Peak E velocity (m/s) | 0.51 ± 0.12 | 0.52 ± 0.11 | 0.50 ± 0.13 | 0.041 |
| Tricuspid Peak A velocity (m/s) | 0.37 ± 0.13 | 0.38 ± 0.13 | 0.36± 0.14 | 0.011 |
| Tricuspid Peak E/A ratio | 1.52 ± 0.61 | 1.501 ± 0.613 | 1.55 ± 0.607 | 0.196 |
| TAPSE (mm) | 23.6 ± 3.3 | 23.2 ± 3.0 | 24.1 ± 3.5 | 0.0001 |
| SPAP (mmHg) | 20.9 ± 5.9 | 21.2 ± 5.3 | 20.7 ± 6.5 | 0.143 |
| TAPSE/SPAP | 1.2 ± 0.4 | 1.1 ± 0.3 | 1.3 ± 0.5 | 0.0001 |
| RVOT AT (m/s) | 138.6 ± 17.5 | 139.6 ± 17.7 | 137.5 ± 17.1 | 0.062 |
| PVR (WU) | 1.3 ± 0.3 | 1.3 ± 0.3 | 1.3 ± 0.4 | 0.605 |
AT, acceleration time; BSA, body surface area; CI, cardiac index (CO/BSA); EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; LA, left atrium; LAVI, left atrial volume indexed to BSA; LV, left ventricular; PVR, pulmonary vascular resistance; RA, right atrial; RV, right ventricular; RVOT, right ventricular outflow tract; SD, standard deviation; SPAP, systolic pulmonary artery pressure; SVI, stroke volume indexed (SV/BSA); TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TRV, tricuspid regurgitation velocity; TVI, time-velocity integral; p values indicate sex-related differences.
MEE and MEEI values in the study population.
| (Mean ± SD) | Lower Limit | Upper Limit | |
|---|---|---|---|
| MEE (mL/s) | |||
| Overall | 61.09 ± 18.19 | 60.05 | 62.13 |
| Male | 67.27 ± 20.18 | 65.59 | 68.95 |
| Female | 54.71 ± 13.13 | 53.67 | 55.75 |
| MEEi (mL/s/g) | |||
| Overall | 0.45 ± 0.14 | 0.44 | 0.46 |
| Male | 0.43 ± 0.13 | 0.42 | 0.44 |
| Female | 0.47 ± 0.14 | 0.45 | 0.48 |
MEE, mechanical efficiency; MEEi, estimated energetic expenditure per unit of myocardial mass; SD, standard deviation.
Figure 1Normal ranges for MEE (A) and MEEi (B) by gender and normal ranges for MEE (C) and MEEi (D) by age.
Figure 2Univariate analysis of MEE (A) and MEEi (B) values by age.
MEE and MEEI values stratified by age in the study population.
| Variables | Age Subgroups (y) | Intragroup | |||
|---|---|---|---|---|---|
| 16–39 years | 40–59 years | >60 years | |||
| (Mean ± SD) | (Mean ± SD) | (Mean ± SD) | |||
| MEE | |||||
| Overall | 59.54 ± 17.44 | 61.41 ± 18.19 | 63.07 ± 19.33 | 0.086 | C: 0.026; |
| Male | 64.92 ± 18.74 | 68.32 ± 20.27 | 69.69 ± 22.56 | 0.15 | |
| Female | 52.59 ± 12.60 | 54.89 ± 13.01 | 57.35 ± 13.74 | 0.01 | C: 0.0031; |
| MEEi | |||||
| Overall | 0.46 ± 0.13 | 0.45 ± 0.14 | 0.43 ± 0.13 | 0.0045 | A: 0.032; C: 0.001; |
| Male | 0.44 ± 0.13 | 0.42 ± 0.14 | 0.42 ± 0.13 | 0.22 | NS |
| Female | 0.49 ± 0.14 | 0.47 ± 0.14 | 0.43 ± 0.14 | <0.001 | A: 0.037; B: 0.025; C: <0.001; |
MEE, mechanical efficiency; MEEi, estimated energetic expenditure per unit of myocardial mass; NS, not significant; SD, standard deviation; y, yeas; intergroup A, age 16–39 vs. age 40–59; intergroup B, age 40–59 vs. age >60; intergroup C, age 16–39 1 vs. age >60.
Figure 3Univariate analysis of MEE (A) and MEEi (B) values.
Multivariate analysis of THE MEE values.
| Estimate | Std. Error | ||
|---|---|---|---|
| (Intercept) | 0.417 | 0.158 | 0.008 |
| Female | −0.146 | 0.024 | <0.001 |
| BSA | 0.219 | 0.070 | 0.001 |
| BMI | −0.003 | 0.003 | 0.331 |
| DBP | −0.003 | 0.001 | <0.001 |
| LAVI | 0.009 | 0.001 | <0.001 |
| E/e’ | 0.015 | 0.005 | 0.003 |
| TAPSE | 0.015 | 0.003 | <0.001 |
BMI, body mass index; BSA, body surface area; DBP, Diastolic blood pressure; LAVI, left atrial volume indexed to BSA; TAPSE, tricuspid annular plane systolic excursion; p values indicate sex-related differences.
Multivariate analysis of the MEEi values.
| Estimate | Std. Error | ||
|---|---|---|---|
| (Intercept) | 0.605 | 0.163 | <0.001 |
| AGE | 0.002 | 0.000 | 0.002 |
| Female | −0.153 | 0.024 | <0.001 |
| BSA | 0.205 | 0.072 | 0.004 |
| BMI | −0.004 | 0.003 | 0.243 |
| SBP | −0.024 | 0.029 | 0.418 |
| DBP | 0.019 | 0.029 | 0.515 |
| PP | 0.023 | 0.029 | 0.426 |
| E/e’ | 0.007 | 0.005 | 0.217 |
| TAPSE | 0.019 | 0.003 | <0.001 |
BMI, body mass index; BSA, body surface area; DBP, diastolic blood pressure, PP, pulse pressure; SBP, systolic blood pressure; TAPSE, tricuspid annular plane systolic excursion; p values indicate sex-related differences.
Previous studies providing MEE and MEEi values [2,3,4,5,6,7,8,18].
| Study | N. | Gender (F/M) | BMI | Age | CVRF | EF | MEE | MEEi | Remarks |
|---|---|---|---|---|---|---|---|---|---|
| De Simone G. et al. | 255 | 151/105 | 27.1 ± 6.6 | 35.3 ± 11.9 | Healthy subjects—no CVRF | 64.6 ± 4.9 | 86.1 ± 25.7 | - | Volunteers involved in a screening program of the department staff or subjects referred to the “Outpatient Nutrition Clinic”. |
| 56 | 26/29 | 27.9 ± 4.8 | 49.3 ± 9.5 | Hypertension | 63.1 ± 6.09 | Low MEE | - | Subjects were divided in groups with normal and low myocardial mechanical efficiency (i.e., below the 90th percentile of the normal distribution; normal distribution: 85.4 ± 22.6) | |
| 250 | 103/148 | 27.9 ± 4.3 | 47.1 ± 10.6 | Hypertension | 66.5 ± 5.4 | Normal MEE | - | ||
| De Simone G. et al. | 12353 | 5429/7008 | - | 52.4 ± 12.5 | Hypertension (100%), obesity (26%), diabetes (10%) * | 66.3 ± 3.9 | 62.6 ± 14.4 | F:0.35 ± 0.08 M:0.33 ± 0.07 | Patients selected from the Campania Salute Network (CSN) Registry. |
| Mancusi C. et al. | 111 | F 42% | 33 ± 5 | 48 ± 9 | Hypertension (85%), obesity (75%), diabetes (10%) ** | 61 ± 6 | - | ≤0.41 | Subjects participating in the fat-associated cardiovascular dysfunction (FATCOR) study. |
| 120 | F 58% | 32 ± 4 | 49 ± 9 | Hypertension (76%), obesity (62%), diabetes (9%) ** | 62 ± 7 | - | 0.42–0.54 | ||
| 125 | F 68% | 32 ± 4 | 46 ± 9 | Hypertension (71%), obesity (67%), diabetes (4%) ** | 64 ± 6 | - | 0.54–0.67 | ||
| 124 | F 75% | 31 ± 4 | 47 ± 9 | Hypertension (65%), obesity (48%), diabetes (7.5%) ** | 63 ± 6 | - | ≥0.67 | ||
| Losi MA. et al. | 478 | F 55% | 60 ± 8 | Hypertension (34%), obesity (58%), diabetes (57%), hyperlipemia (62%), former smoker (38%), current smoker (35%) * | - | - | ≤0.34 | Data from the “Strong Heart Study” (SHS), a population-based cohort with CVRF but free of CV disease. | |
| 479 | F 65% | 59 ± 8 | Hypertension (29%), obesity (57%), diabetes (41%), hyperlipemia (59%), former smoker (36%), current smoker (34%) * | - | - | 0.35–0.39 | |||
| 477 | F 69% | 60 ± 8 | Hypertension (25%), obesity (51%), diabetes (37%), hyperlipemia (55%), former smoker (34%), current smoker (35%) * | - | - | 0.40–0.44 | |||
| 478 | F 68% | 59 ± 8 | Hypertension (22%), obesity (40%), diabetes (25%), hyperlipemia (57%), former smoker (33%), current smoker (39%) * | - | - | ≥0.45 | |||
| Manzi MV. et al. | 5536 | F 42.1% | 53.40 ± 11.41 | Hypertension (100%), obesity (24.3%), diabetes (9.8%), smoker (19.1%) * | 65.8 ± 3.86 | - | 0.34 ± 0.07 | Patients selected from the Campania Salute Network (CSN) Registry. | |
| 137 | F 38% | 59.46 ± 11.58 | Hypertension (100%), obesity (27%), diabetes (18.2%), smoker (19%) * | 65.2 ± 11.5 | - | 0.32 ± 0.08 | |||
| Bahlmann E. et al. | 569 | F 35% | 27.9 ± 4.7 | 68 ± 10 | Hypertension (88%), obesity (28%) *** | 65 ± 7 | - | <0.34–0.26 ± 0.06 | Post hoc analysis performed within the prospective Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. |
| 1134 | F 41% | 26.3 ± 4.1 | 67 ± 10 | Hypertension (81%), obesity (16%) *** | 67 ± 6 | - | ≥0.34–0.54 ± 0.16 | ||
| Fiorentino TV et al. | 617 NGT 1 h-low (1) | 389/228 | 29.4 ± 6.6 | 44 ± 13 | ≥1 cardio-metabolic risk factors **** | - | - | 0.41 ± 0.11 | The study cohort consisted of 1467 non-diabetic adult subjects participating in the CATAMERI study. |
| 210 NGT 1 h-high (2) | 100/110 | 30.1 ± 5.9 | 49 ± 12 | ≥1 cardio-metabolic risk factors **** | - | - | 0.38 ± 0.11 | ||
| 237 Isolated IFG (3) | 94/143 | 30.3 ± 5.3 | 54 ± 11 | ≥1 cardio-metabolic risk factors **** | - | - | 0.37 ± 0.10 | ||
| 403 IGT (4) | 217/186 | 31.4 ± 5.9 | 54 ± 12 | ≥1 cardio-metabolic risk factors **** | - | - | 0.35 ± 0.09 | ||
| Cioffi G. et al. | 432 | F 64% | 26.0 ± 4.5 | 57 ± 12 | Hypertension (46%), obesity (16%), diabetes (9%), hyperlipemia (56%), active smoker (34%) | 66 ±7 | - | 0.35 ± 0.11 | The study population consisted of 432 outpatients with established chronic inflammatory arthritis without overt cardiac disease, compared to 216 patients without chronic inflammatory arthritis. |
| 216 | F 58% | 25.4 ± 4.3 | 59 ± 14 | Hypertension (46%), obesity (16%), diabetes (9%), hyperlipemia (56%), active smoker (34%) | 64 ± 9 | - | 0.45 ± 0.10 |
The table collects the values of MEE and MEEi provided by previous studies. Most studies included subjects with different cardio-metabolic risk factors, except for one study of 255 healthy subjects [3]. BMI, body mass index; CV, cardiovascular; CVRF, cardiovascular risk factors; EF, ejection fraction; IFG, impaired glucose tolerance; MEE, myocardial mechanical efficiency; MEEi, indexed myocardial mechanical efficiency; NGT, normal glucose tolerance. * Arterial hypertension was defined as office BP values at least 140 (SBP) and/or at least 90 mmHg (DBP) or when participants were taking antihypertensive medications. Obesity was defined as a BMI of at least 30 kg/m2. Diabetes was defined as fasting plasma glucose >125 mg/dL or current antidiabetic treatment. ** Hypertension was considered present if the 24 h ambulatory BP was elevated or if the participants reported the use of antihypertensive medications. Obesity was defined as BMI ≥30.0 kg/m2. Diabetes mellitus was considered present if fasting blood glucose ≥7 mmol/L, 2 h blood glucose ≥11.1 mmol/L after a 75 g oral glucose test, or glycated hemoglobin A1c ≥6.5%. *** Obesity was defined as body mass index ≥30 kg/m2. Hypertension was defined as history of hypertension or current antihypertensive treatment or elevated blood pressure at the baseline clinical visit. **** Cardio-metabolic risk factors included family history of diabetes, dysglycemia, hypertension, dyslipidemia, and overweight/obesity. Individuals were classified as having normal glucose tolerance (NGT) when fasting plasma glucose was < 100 mg/dL and 2 h post-load glucose was <140 mg/dL; isolated impaired fasting glucose (IFG) when fasting plasma glucose was 100–125 mg/dL and 2 h post-load glucose was <140; impaired glucose tolerance (IGT) when 2 h post-load glucose was 140–199 mg/dL in accordance with the ADA criteria. Individuals with NGT were further subdivided into two groups (NGT 1 h-low and NGT 1 h-high) using the 1 h plasma glucose cut-off of 155 mg/dL.